Search
The results of your search are listed below. To view the details of a trial or study, click on the "SEE DETAILS" button. Or start a new search.
Searched for: advanced ovarian. 9 results shown below.
Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer
Complete title: Lavage of the Uterine Cavity for Diagnosis of Ovarian Carcinomas
Principal Investigator: Barbara Norquist, MD
Study Number: 10019
Phase: N/A
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Complete title: Phase I Study Evaluating Benefit of PRGN-3005 (Autologous CAR T Cells) Delivered by Intraperitoneal Infusion (IP) or Intravenous Infusion (IV) in Advanced Stage Platinum Resistant Ovarian Cancer Patients
Principal Investigator: John Liao, MD, PhD
Study Number: 10056
Phase: I
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Complete title: A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients with Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Principal Investigator: Sylvia Lee, MD
Study Number: 10501
Phase: I
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)
Complete title: An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Principal Investigator: Gabriela Chiorean
Study Number: 20152369
Phase: II
A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors
Complete title: A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, An Oral RAD51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Principal Investigator: Ryan Lynch
Study Number: RG1006339
Phase: I/II
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Complete title: A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Principal Investigator: John Thompson, MD
Study Number: RG1006384
Phase: I
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Complete title: A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination with Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients with Advanced Solid Tumors
Principal Investigator: John Liao, MD, PhD
Study Number: RG1007497
Phase: I/II
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
Complete title: A Multicenter, Open-Label, Parallel, Phase 2a Study of PLX2853 Monotherapy in Advanced Gynecological Malignancies with a Known ARID1A Mutation and Phase 1b/2a Study of PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer
Principal Investigator: Elizabeth Swisher, MD
Study Number: RG1007920
Phase: I/II
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Complete title: Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies
Principal Investigator: Gabriela Chiorean
Study Number: RG1121312
Phase: N/A